Filing Flows › Accuray (ARAY) › Guidance & outlook

Accuray (ARAY) guidance and outlook

Accuray's 10-Q filed Nov 6, 2026 makes 20 forward-looking statements.

Guidance and outlook

Forward-looking statements, 10-Q filed Nov 6, 2026

• We believe these solutions provide clinicians with advanced capabilities to support accuracy, flexibility, motion management, image guidance, adaptive workflows and personalized treatment delivery.
• We expect that the business of our customers and our own business will continue to be adversely impacted, directly or indirectly, by these macroeconomic and geopolitical issues.
• In addition, ongoing supply chain challenges and logistics costs, including difficulties in obtaining a sufficient supply of component materials and increased component costs, have adversely affected our gross margins and net income (loss), and we currently expect that gross margins and net income (loss) will continue to be adversely affected by increased material costs and freight and logistics expenses through…
• In addition, we expect inflation and the ongoing supply chain challenges and logistics costs to impact our cash from operations through at least fiscal year 2027 .
• In addition, reduced budgets and lower capital deployment priority for radiotherapy equipment, along with longer customer installation timelines, in the United States have negatively impacted our net revenue since fiscal year 2024, and we expect this will continue to affect us.
• There remains significant tariff uncertainty, including related to existing tariffs associated with U.S.-China trade, which we expect will continue to result in incremental costs to us.
• If existing tariffs increase, we would expect minimal shipments to China despite customer demand.
• We continue to work to implement mitigations to the tariff policy impacts; however, we cannot predict the full impact or timing of such efforts and expect that sales to China will be adversely impacted, and our financial results have been adversely impacted in the past and may continue to be adversely impacted in the future.
• We also continue to evaluate our operating expenses to conserve cash in light of the uncertain macroeconomic environment due to tariffs, and to evaluate our real estate needs and continue to assess our operations and how and to what extent we will continue to utilize our current real estate assets.
• The JV aims to be uniquely positioned to serve China, which we believe is the world’s largest growth market for radiation oncology systems.
• We believe this strategy will allow us to best maximize both near and longer-term opportunities in China.
• We intend to implement the Reverse Stock Split to increase the per-share trading price of our common stock and assist us in regaining compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Accuray's latest quarter

Questions

What does Accuray expect?

We believe these solutions provide clinicians with advanced capabilities to support accuracy, flexibility, motion management, image guidance, adaptive workflows and personalized treatment delivery. We expect that the business of our customers and our own business will continue to be adversely impacted, directly or indirectly, by these macroeconomic and geopolitical issues. In addition, ongoing supply chain challenges and logistics costs, including difficulties in obtaining a sufficient supply of component materials and increased component costs, have adversely affected our gross margins and ne

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.